IRIS
TORNIAI, MARIANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.510
EU - Europa 494
AS - Asia 174
AF - Africa 44
Totale 2.222
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.510
IT - Italia 112
UA - Ucraina 87
IE - Irlanda 78
SE - Svezia 75
SG - Singapore 63
DE - Germania 49
CN - Cina 47
TR - Turchia 39
CI - Costa d'Avorio 34
FI - Finlandia 26
DK - Danimarca 25
KR - Corea 15
BE - Belgio 14
GB - Regno Unito 14
FR - Francia 11
MA - Marocco 10
IN - India 9
JP - Giappone 1
LT - Lituania 1
NL - Olanda 1
RU - Federazione Russa 1
Totale 2.222
Salva come PNG Salva come JPEG
Città #
Chandler 218
Fairfield 139
Ashburn 134
Jacksonville 131
Des Moines 113
Dublin 78
Wilmington 73
Boardman 68
Woodbridge 58
New York 56
Seattle 54
Houston 51
Cambridge 49
Ann Arbor 37
Abidjan 34
Lawrence 31
Princeton 31
Turin 31
San Mateo 30
Singapore 29
Brussels 14
San Diego 14
Washington 14
Los Angeles 13
Helsinki 12
Centro 10
Falls Church 9
Pune 9
Beijing 7
Norwalk 7
Kilburn 6
Shanghai 6
Guangzhou 5
Dallas 4
Ancona 3
Jiaxing 3
London 3
Montegiorgio 3
Castelraimondo 2
Chengdu 2
Cupra Marittima 2
Hounslow 2
Hyattsville 2
Porto 2
Shenzhen 2
Wuxi 2
Bevagna 1
Cernusco sul Naviglio 1
Chiswick 1
Chizhou 1
Foligno 1
Fuzhou 1
Genoa 1
Harrison 1
Mondolfo 1
Munich 1
New Bedfont 1
Quanzhou 1
Redwood City 1
San Severino Marche 1
Sano 1
Seoul 1
Trecastelli 1
Wuhan 1
Totale 1.621
Salva come PNG Salva come JPEG
Nome #
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 93
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach 91
Electrolyte disorders in cancer patients: a systematic review 87
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma 85
Hyponatremia in cancer patients: Time for a new approach 84
Gender differences and outcome of melanoma patients 84
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 83
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 83
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma 82
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 82
Benefits and limitations of a multidisciplinary approach in cancer patient management 80
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. 79
Gender Differences and Outcomes in Melanoma Patients 79
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 75
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 74
Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex 72
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 72
High CTLA-4 expression correlates with poor prognosis in thymoma patients 72
Medical treatment for gastro-entero-pancreatic neuroendocrine tumours 71
Systemic treatment for lung carcinoids: from bench to bedside 71
Locally advanced rectal cancer: the importance of a multidisciplinary approach. 70
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 68
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 66
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis 66
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 66
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 66
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 65
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 63
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study 55
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 50
Medical Treatment in Gastroenteropancreatic Neuroendocrine Neoplasms: a look into the future. 43
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET) 8
Totale 2.285
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.029
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.029
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020126 0 0 0 0 16 0 15 0 18 13 18 46
2020/2021551 36 50 80 24 67 32 27 45 55 51 48 36
2021/2022246 16 36 14 3 7 30 11 12 28 24 25 40
2022/2023666 40 78 42 58 30 165 0 35 128 4 70 16
2023/2024360 51 6 31 22 48 107 7 25 1 15 1 46
2024/2025160 71 53 17 4 15 0 0 0 0 0 0 0
Totale 2.285